Tetraphase Pharmaceuticals begins dosing of first patient in IGNITE4 trial of eravacycline to treat cIAI

Tetraphase Pharmaceuticals has announced the dosing of its first patient in IGNITE4, the phase 3 clinical study analysing the efficacy and safety of intravenous (IV) eravacycline compared to meropenem in complicated intra-abdominal infections (cIAI). …

Source: Drug Development Technology - October 16, 2016 Category: Pharmaceuticals Source Type: news